LeMaitre Vascular, Inc. (LMAT)
| Market Cap | 1.92B -11.7% |
| Revenue (ttm) | 262.43M +11.8% |
| Net Income | 65.67M +39.4% |
| EPS | 2.86 +39.4% |
| Shares Out | 22.87M |
| PE Ratio | 29.35 |
| Forward PE | 27.44 |
| Dividend | $1.00 (1.19%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 252,041 |
| Open | 82.15 |
| Previous Close | 81.52 |
| Day's Range | 81.57 - 84.12 |
| 52-Week Range | 78.65 - 118.01 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 107.00 (+27.58%) |
| Earnings Date | Aug 4, 2026 |
About LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter... [Read more]
Financial Performance
In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $107.0, which is an increase of 27.58% from the latest price.
News
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diag...
LeMaitre upgraded to Outperform from Market Perform at Barrington
Barrington upgraded LeMaitre (LMAT) to Outperform from Market Perform with a $95 price target The firm, which downgraded LeMaitre shares yesterday before the market open, views the decline of over…
LeMaitre downgraded to Market Perform from Outperform at Barrington
Barrington downgraded LeMaitre (LMAT) to Market Perform from Outperform without a price target following the Q2 report. The miss versus the company’s own financial guidance will result in “significant...
LeMaitre Vascular Earnings Call Transcript: Q2 2026
Q2 2026 saw 10% organic sales growth, led by Artegraft and strong EMEA/APAC performance, while EPS rose 23% and gross margin reached 72.1%. Guidance was trimmed to 11% organic growth due to FX, export delays, and supply constraints, but profitability and cash flow remain robust.
LeMaitre Vascular Earnings release: Q2 2026
LeMaitre Vascular released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
LeMaitre Vascular Quarterly report: Q2 2026
LeMaitre Vascular has published its Q2 2026 quarterly earnings report on August 4, 2026.
LeMaitre Q2 2026 Financial Results
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarter...
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, af...
LeMaitre to Participate at Upcoming Investor Conferences in June
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
LeMaitre to Present at the Bank of America Healthcare Conference
BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 1...
LeMaitre price target raised to $127 from $118 at Citizens
Citizens analyst Daniel Stauder raised the firm’s price target on LeMaitre (LMAT) to $127 from $118 and keeps an Outperform rating on the shares. LeMaitre continues to demonstrate strong execution,…
LeMaitre price target raised to $120 from $105 at Barrington
Barrington raised the firm’s price target on LeMaitre (LMAT) to $120 from $105 and keeps an Outperform rating on the shares. The firm views the company’s Q1 report as solid.
LeMaitre price target raised to $135 from $110 at Lake Street
Lake Street analyst Frank Takkinen raised the firm’s price target on LeMaitre (LMAT) to $135 from $110 and keeps a Buy rating on the shares. After “a clean Q1,” the…
LeMaitre Vascular Earnings Call Transcript: Q1 2026
Q1 2026 delivered 11% sales growth, 72.7% gross margin, and 42% EPS growth, driven by strong performance across all product categories and geographies. Artegraft led growth, with international sales expected to more than double in 2026. Full-year guidance was raised for revenue, margins, and EPS.
LeMaitre Vascular Earnings release: Q1 2026
LeMaitre Vascular released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
LeMaitre Vascular Quarterly report: Q1 2026
LeMaitre Vascular has published its Q1 2026 quarterly earnings report on May 5, 2026.
LeMaitre Vascular Slides: Q1 2026
LeMaitre Vascular has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
LeMaitre Q1 2026 Financial Results
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterl...
LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after...
LeMaitre Vascular Proxy statement: Proxy filing
LeMaitre Vascular filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
LeMaitre Vascular Proxy statement: Proxy filing
LeMaitre Vascular filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thu...
LeMaitre initiated with a Hold at Freedom Capital
Freedom Capital initiated coverage of LeMaitre (LMAT) with a Hold rating and $113 price target The peripheral vascular surgery focused medtech company has leadership positions in niche markets across ...